FIGURE 4.

Recombinant human insulin‐like growth factor‐binding protein 5 (IGFBP5) suppresses tube formation, cell proliferation and migration. (A) Representative images and (B) quantification of tube formation in recombinant human IGFBP5 (rhIGFBP5)‐ or vehicle‐treated human umbilical vein endothelial cells (HUVECs). (C) Representative immunofluorescence images and (G) quantification of 5‐ethynyl‐2′‐deoxyuridine (EdU, green)‐stained HUVECs treated with rhIGFBP5 or vehicle (n = 5 in each group). (E) Representative images and (F) quantification of flow cytometry for cell cycle in rhIGFBP5‐ or vehicle‐treated HUVECs (n = 5 in each group). (G) Representative images and (H) quantification of wound healing assay in rhIGFBP5‐ or vehicle‐treated HUVECs. (I) Representative images and (J) quantification of transwell assay in rhIGFBP5‐ or vehicle‐treated HUVECs (n = 5 in each group). Representative Western blotting images and quantification of (K) p‐IGF1R and IGF1R, (L) p‐Erk1/2 and Erk1/2 and (M) p‐Akt, and Akt in rhIGFBP5‐ or vehicle‐treated HUVECs (n = 6 in each group).